FindMyKOL
Clinical trialNCT00377455TerminatedPhase 2Interventional

Placebo Controlled Trial of Bosentan in Scleroderma Patients

NCT00377455 is a phase 2 interventional trial sponsored by Georgetown University. As of 21 Nov 2026, it was terminated. It studies Bosentan monohydrate and Placebo in Pulmonary Hypertension and Systemic Scleroderma. The registry lists an enrollment of 5 participants at 2 sites in 1 country. The registry lists a start date of 30 Sept 2006 and a primary completion date of 30 Sept 2009.

SponsorGeorgetown University →Enrollment5Pulmonary HypertensionSystemic Scleroderma
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00377455
FieldValue
Registry IDNCT00377455
StatusTerminated
PhasePhase 2
Study typeInterventional trial
Lead sponsorGeorgetown University
Enrollment5
Registered sites2
Countries1
ConditionsPulmonary Hypertension and Systemic Scleroderma
DrugsBosentan monohydrate and Placebo
Start30 Sept 2006
Primary completion30 Sept 2009
Study completion31 Mar 2010
Last update posted24 May 2018

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine whether the drug Bosentan improves exercise tolerance in scleroderma patients.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Connecticut, United States1 site
  • University of Connecticut

    Farmington

District of Columbia, United States1 site
  • Georgetown University Medical Center

    Washington D.C.

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticut: 1 siteCT1CaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of Columbia: 1 siteDC1
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00377455

Each answer restates registry values shown on this page.

What is NCT00377455?

NCT00377455 is a phase 2 interventional trial sponsored by Georgetown University. It studies Bosentan monohydrate and Placebo in Pulmonary Hypertension and Systemic Scleroderma.

Who leads NCT00377455?

The registry names Virginia D Steen, MD (principal investigator, Georgetown University) as the overall official.

Where does NCT00377455 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00377455 study?

The registered drug and biological interventions are Bosentan monohydrate and Placebo.

When did NCT00377455 end?

The registry lists a primary completion date of 30 Sept 2009 and a study completion date of 31 Mar 2010. The sponsor last updated the record on 24 May 2018.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.